Please complete all 3 questions below and click 'Submit'. You must answer a minimum of 3 questions correctly to earn a CE certificate.
a. AML with myelodysplasia-related changes
b. ECOG 0 or 1
c. Poor cytogenetic risk at induction
d. All of the above
a. Crenolanib
b. Sorafenib
c. Quizartinib
d. Midostaurin
a. Hypomethylating agent plus venetoclax
b. Oral azacitidine
c. Low-dose cytarabine plus glasdegib
d. FLT3 inhibitor with or without venetoclax

 

 

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, Dr. Desai will explore new approaches to maintenance therapy in AML. Topics include a discussion of the study design and results of the QUAZAR AML-001 trial of oral azacitidine for maintenance therapy, findings from the RATIFY study that led to the approval of midostaurin for FLT3-mutated AML, sorafenib for post-allogeneic stem cell transplant maintenance, and decitabine plus recombinant human granulocyte colony-stimulating factor in the post-transplant setting.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of maintenance therapy in prolonging the remission interval in the post-consolidation setting
  • Identify ongoing and planned studies evaluating promising novel targeted therapies under investigation as maintenance therapy in AML
  • Integrate supporting clinical evidence when planning maintenance therapy for eligible patients with AML

Agenda

New Treatment Paradigms in AML: A Focus on Maintenance Therapy – Pinkal Desai, MD, MPH

Instructions for Participation and Credit

This activity is eligible for credit through April 21, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Pinkal Desai, MD, MPH
Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
New York-Presbyterian Hospital
New York, New York

Dr. Pinkal Desai received her MBBS at Byram Jeejeebhoy Medical College in India, and her MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in hematology-medical oncology at Providence Hospital Medical Center, serving as chief fellow. Dr. Desai is currently an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the New York-Presbyterian Hospital. In addition, she is a faculty member in the Weill Cornell Leukemia Program, and has a clinical practice devoted to leukemia, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). Dr. Desai is actively involved in clinical and translational research protocols and projects in these areas. Her expertise is in clinical care of patients with these diseases and she serves as co/principal investigator of numerous clinical trials.

Dr. Desai is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has served on the ASCO University Committee. Her research interests are in hematologic malignancies, particularly in the fields of MDS, AML, and clonal hematopoiesis. In addition, Dr. Desai has a background in epidemiology and has a strong research interest in the epidemiology of hematologic malignancies, particularly in studying preventative strategies in hematological malignancies, with numerous publications in the field of cancer epidemiology. She has numerous peer-reviewed publications in oncology and epidemiology, and is published in journals including Nature, Nature Medicine, Blood Advances, and Cancer Medicine. Dr. Desai is also the Clinical Director of the Molecular Aging Institute at Englander Institute Precision Medicine where she leads a team of scientists, clinicians, statisticians, and bioinformatics to develop and oversee numerous projects in clonal hematopoiesis

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.

©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

MediCom CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-023-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Pinkal Desai has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation – A Bristol-Myers Squibb Company, Kura Oncology, Inc., and Takeda Oncology. She has received grant support related to research activities from Astex Pharmaceuticals and Janssen Pharmaceuticals, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.